Michael Peluso

Early Antiviral Treatment to Prevent Viral Persistence and Inflammation as Drivers of Long COVID: A Proof-of-Concept Mechanistic Trial

National Institute of Allergy and Infectious Diseases · U01

Contact PI · $1.7M · University of California, San Francisco

Assessing the Mechanisms Underlying Female Sex-Predominance in Long COVID

National Institute of Allergy and Infectious Diseases · R01

Contact PI · $1.8M · University of California, San Francisco

Broadening the Scale and Impact of a Comprehensive Long COVID Clinic to Serve Diverse Patient Groups with Multidisciplinary Care and Research Access

Agency for Healthcare Research and Quality · U18

PI · $3M · University of California, San Francisco

Evaluating SARS-CoV-2 Spike Antigen-Induced Coagulopathy and Neuroinflammation as Mechanistic Drivers of Neurologic PASC

National Institute of Neurological Disorders and Stroke · R01

Contact PI · $2M · University of California, San Francisco

Chronic Infections and Inflammation in ME/CFS: An Observational Study

Principal investigator · Recruiting

University of California, San Francisco

Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

Principal investigator · Active not recruiting · Phase 2

Timothy Henrich

Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

Principal investigator · Active not recruiting · Phase 2

Michael Peluso, MD

Long-term Impact of Infection With Novel Coronavirus (COVID-19)

Principal investigator · Recruiting

University of California, San Francisco